Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCYAP1R1 | P41586 | 7/20 | 0.70 |
| ▸ | GCGR | P47871 | 11/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664614 | 0.90 | ADCYAP1R1 (0.62) | ADCYAP1R1GCGRSPHK2SPHK1MEN1 | |
| SCHEMBL2664378 | 0.89 | ADCYAP1R1 (0.65) | ADCYAP1R1GCGRSPHK2SPHK1MEN1 | |
| SCHEMBL2664167 | 0.87 | ADCYAP1R1 (0.60) | ADCYAP1R1GCGRMEN1KMT2A | |
| SCHEMBL2664440 | 0.87 | ADCYAP1R1 (0.69) | ADCYAP1R1GCGRSPHK2SPHK1MEN1 | |
| SCHEMBL2664434 | 0.86 | ADCYAP1R1 (0.59) | ADCYAP1R1GCGR | |
| SCHEMBL9072136 | 0.86 | ADCYAP1R1 (0.59) | ADCYAP1R1GCGRMAPT | |
| SCHEMBL2664449 | 0.85 | ADCYAP1R1 (0.58) | ADCYAP1R1GCGR | |
| SCHEMBL9072405 | 0.84 | ADCYAP1R1 (0.61) | ADCYAP1R1GCGR | |
| SCHEMBL2664444 | 0.84 | ADCYAP1R1 (0.61) | ADCYAP1R1GCGRMAPTRAB9AKMT2A | |
| SCHEMBL9072164 | 0.83 | ADCYAP1R1 (0.56) | ADCYAP1R1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |